Home
Fairmount Funds Management reported a 3.1% stake in Enliven Therapeutics ELVN · 1,855,644 sh · amendment · passive holder
Trade details
- Type
- 5% stake report
- Report
- 13G passive · amendment
- Stake
- 3.1%
- Last report
- 6.3% · filed 25/08/14
- Shares held
- 1,855,644 sh
- Class
- Common Stock, par value $0.001 per share
- Event date
- 26/03/31
- Filed
- 26/05/15
3.1% stake · below 5%
- Stake
- 3.1%
- Last report
- 6.3%
- Since last report
- −3.2pp
Enliven Therapeutics trades, last 26 weeks
What else happened in Enliven Therapeutics around then
Filed or reported within 30 days of the trade day · 03/01~04/30Fairmount Funds Management's other 5% stake reports
- Fairmount Funds Management
5% stakeKorsana Biosciences
5% stakeKorsana Biosciences
KRSA
19.99% stake
9,106,420 sh
19.99% stake
Filed 09/11
- Fairmount Funds Management
5% stakeCrescent Biopharma
5% stakeCrescent Biopharma
CBIO
16.52% stake
6,602,408 sh
16.52% stake
Filed 07/20
- Fairmount Funds Management
5% stakeOruka Therapeutics
5% stakeOruka Therapeutics
ORKA
19.5% stake
14,572,917 sh
19.5% stake
Filed 07/01
- Fairmount Funds Management
5% stakeSpyre Therapeutics
5% stakeSpyre Therapeutics
SYRE
9.99% stake
9,667,201 sh
9.99% stake
Filed 06/23
- Fairmount Funds Management
5% stakeJade Biosciences
5% stakeJade Biosciences
JBIO
19.99% stake
14,069,494 sh
19.99% stake
Filed 06/09
